Long-acting cabotegravir injection safety in healthy adults
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This Phase 1 study tests how the body handles a long-acting (slow-release) cabotegravir injection combined with a drug called hyaluronidase. It also checks safety and side effects in healthy adults to help future HIV-prevention or treatment plans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 55 years old and able to sign consent in writing
- Be generally healthy based on medical history, exam, blood/urine tests, and heart monitoring
- Weigh at least 40 kg and have a BMI between 18 and 32
- Test negative for COVID-19 by PCR on the day you enter the study
- Use birth control consistently with local study rules (if applicable)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows adults with well-controlled HIV who are planning to switch to a long-acting HIV medicine given as injections. It may help researchers understand how this approach works for people already stable on current treatment.
This study tests a new long-acting medicine that may help prevent HIV. It is given as an injection, and the study checks how safe it is and how it works in healthy volunteers.
This trial tests a new ultra-long-acting injectable combination of cabotegravir and rilpivirine for people with HIV who already have the virus under control. It aims to see if these shots can keep the virus suppressed with fewer doses.
This study tests a new injectable drug (VH4011499) for safety and how the body processes it. It's for healthy adults without HIV, and participants will get either the study drug or a placebo (an inactive shot).
This study tests a long-acting injectable HIV prevention medicine called cabotegravir in newborn babies who were exposed to HIV. The goal is to see if it can help protect them from getting HIV.
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.